Patents by Inventor Toru Mizushima
Toru Mizushima has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20200370025Abstract: An agent for treating acute respiratory distress syndrome includes, as an active ingredient, a lecithinized superoxide dismutase represented by the general formula (I): SOD?(Q-B)m??(I) (wherein, SOD? represents a residue of a superoxide dismutase; Q represents a chemical crosslinking; B represents a residue of lysolecithin, in which a hydrogen atom of a hydroxyl group is removed from the lysolecithin having the hydroxyl group at the 2-position of glycerol; and m is the average number of bonds of the lysolecithin relative to one molecule of the superoxide dismutase and represents an integer of 1 or more).Type: ApplicationFiled: August 4, 2020Publication date: November 26, 2020Inventor: Toru MIZUSHIMA
-
Publication number: 20180320148Abstract: An agent for treating acute respiratory distress syndrome includes, as an active ingredient, a lecithinized superoxide dismutase represented by the general formula (I): SOD?(Q-B)m??(I) (wherein, SOD? represents a residue of a superoxide dismutase; Q represents a chemical crosslinking; B represents a residue of lysolecithin, in which a hydrogen atom of a hydroxyl group is removed from the lysolecithin having the hydroxyl group at the 2-position of glycerol; and m is the average number of bonds of the lysolecithin relative to one molecule of the superoxide dismutase and represents an integer of 1 or more).Type: ApplicationFiled: October 4, 2016Publication date: November 8, 2018Inventor: Toru MIZUSHIMA
-
Patent number: 9539248Abstract: This invention provides a safe and effective agent for ameliorating chronic obstructive pulmonary disease (COPD) that has both a bronchodilator effect and an anti-inflammatory effect. The agent for ameliorating chronic obstructive pulmonary disease contains mepenzolate bromide as an active ingredient. More preferably the mode of administration of the agent for ameliorating chronic obstructive pulmonary disease is airway administration or inhalation administration, and furthermore the mode of administration thereof is oral administration or rectal administration. This invention is a safe and effective agent for ameliorating chronic obstructive pulmonary disease (COPD) that has both a bronchodilator effect and an anti-inflammatory effect of mepenzolate bromide.Type: GrantFiled: May 22, 2015Date of Patent: January 10, 2017Assignee: LTT Bio-Pharma Co., Ltd.Inventors: Toru Mizushima, Hongxing Liu
-
Publication number: 20160368873Abstract: An optically active form of mepenzolate bromide is provided. An agent for ameliorating chronic obstructive pulmonary disease that contains the optically active form as an active ingredient and is based on a bronchodilator effect and an anti-inflammatory effect is also provided. (3R)- or (3S)-3-[(hydroxy)(diphenyl)acetoxy]-1,1-dimethylpiperidinium bromide (hereinafter referred to as “(R)- or (S)-mepenzolate bromide”) is provided. An agent for ameliorating chronic obstructive pulmonary disease that contains the (R)- or (S)-mepenzolate bromide as an active ingredient is provided. Furthermore, an agent for ameliorating chronic obstructive pulmonary disease whose mode of administration is airway administration or inhalation administration is provided.Type: ApplicationFiled: June 16, 2014Publication date: December 22, 2016Inventor: Toru MIZUSHIMA
-
Patent number: 9221786Abstract: Provided are novel 2-fluorophenyl propionic acid derivatives which have excellent anti-inflammatory/analgesic effects while avoiding side effects such as gastrointestinal disorders, namely 2-fluorophenyl propionic acid derivatives represented by the formula (I) below or pharmaceutically acceptable salts thereof, [wherein, R1 represents a hydrogen atom, a halogen atom, or a substituted or unsubstituted phenyl group, X represents —CH2—, —NH—, —O—, or —S—, and Y specifically represents group (II) (wherein, Z1 represents —CO—, —CH(OH)—, or —CH2—, and n represents an integer of 1 or 2.Type: GrantFiled: December 6, 2012Date of Patent: December 29, 2015Assignee: LTT Bio-Pharma Co., Ltd.Inventors: Toru Mizushima, Masami Otsuka, Yoshinari Okamoto, Naoki Yamakawa
-
Patent number: 9161986Abstract: There is provided a beraprost sodium-containing nanoparticle that contains beraprost sodium among other prostaglandin I2 (prostacyclin) derivatives, which are therapeutic agents for pulmonary hypertension. The beraprost sodium-containing nanoparticle is obtained by making beraprost sodium hydrophobic using a metal ion and allowing the hydrophobic beraprost sodium to react with poly-L-lactic acid or a poly(L-lactic acid/glycolic acid) copolymer, and a poly-DL- or L-lactic acid-polyethylene glycol block copolymer or a poly(DL- or L-lactic acid/glycolic acid)-polyethylene glycol block copolymer. The beraprost sodium-containing nanoparticle excels in sustained release of an active ingredient, reduces a side effect, and furthermore, has an excellent drug retention in the blood. Therefore, the beraprost sodium-containing nanoparticle is quite outstanding particularly regarding the sustainability of the medicinal effect.Type: GrantFiled: February 13, 2012Date of Patent: October 20, 2015Assignee: LTT BIO-PHARMA CO., LTD.Inventors: Toru Mizushima, Tsutomu Ishihara, Hongxing Liu
-
Publication number: 20150250779Abstract: This invention provides a safe and effective agent for ameliorating chronic obstructive pulmonary disease (COPD) that has both a bronchodilator effect and an anti-inflammatory effect. The agent for ameliorating chronic obstructive pulmonary disease contains mepenzolate bromide as an active ingredient. More preferably the mode of administration of the agent for ameliorating chronic obstructive pulmonary disease is airway administration or inhalation administration, and furthermore the mode of administration thereof is oral administration or rectal administration. This invention is a safe and effective agent for ameliorating chronic obstructive pulmonary disease (COPD) that has both a bronchodilator effect and an anti-inflammatory effect of mepenzolate bromide.Type: ApplicationFiled: May 22, 2015Publication date: September 10, 2015Inventors: Toru MIZUSHIMA, Hongxing LIU
-
Publication number: 20150038719Abstract: This invention provides a safe and effective agent for ameliorating chronic obstructive pulmonary disease (COPD) that has both a bronchodilator effect and an anti-inflammatory effect. The agent for ameliorating chronic obstructive pulmonary disease contains mepenzolate bromide as an active ingredient. More preferably the mode of administration of the agent for ameliorating chronic obstructive pulmonary disease is airway administration or inhalation administration, and furthermore the mode of administration thereof is oral administration or rectal administration. This invention is a safe and effective agent for ameliorating chronic obstructive pulmonary disease (COPD) that has both a bronchodilator effect and an anti-inflammatory effect of mepenzolate bromide.Type: ApplicationFiled: February 28, 2013Publication date: February 5, 2015Inventors: Toru Mizushima, Hongxing Liu
-
Publication number: 20140330026Abstract: Provided are novel 2-fluorophenyl propionic acid derivatives which have excellent anti-inflammatory/analgesic effects while avoiding side effects such as gastrointestinal disorders, namely 2-fluorophenyl propionic acid derivatives represented by the formula (I) below or pharmaceutically acceptable salts thereof, [wherein, R1 represents a hydrogen atom, a halogen atom, or a substituted or unsubstituted phenyl group, X represents —CH2—, —NH—, —O—, or —S—, and Y specifically represents group (II) (wherein, Z1 represents —CO—, —CH(OH)—, or —CH2—, and n represents an integer of 1 or 2.Type: ApplicationFiled: December 6, 2012Publication date: November 6, 2014Inventors: Toru Mizushima, Masami Otsuka, Yoshinari Okamoto, Naoki Yamakawa
-
Publication number: 20140050690Abstract: There is provided a beraprost sodium-containing nanoparticle that contains beraprost sodium among other prostaglandin I2 (prostacyclin) derivatives, which are therapeutic agents for pulmonary hypertension. The beraprost sodium-containing nanoparticle is obtained by making beraprost sodium hydrophobic using a metal ion and allowing the hydrophobic beraprost sodium to react with poly-L-lactic acid or a poly(L-lactic acid/glycolic acid) copolymer, and a poly-DL- or L-lactic acid-polyethylene glycol block copolymer or a poly(DL- or L-lactic acid/glycolic acid)-polyethylene glycol block copolymer. The beraprost sodium-containing nanoparticle excels in sustained release of an active ingredient, reduces a side effect, and furthermore, has an excellent drug retention in the blood. Therefore, the beraprost sodium-containing nanoparticle is quite outstanding particularly regarding the sustainability of the medicinal effect.Type: ApplicationFiled: February 13, 2012Publication date: February 20, 2014Applicant: LTT Bio-Pharma Co., Ltd.Inventors: Toru Mizushima, Tsutomu Ishihara, Hongxing Liu
-
Publication number: 20140023629Abstract: An ameliorating agent for chronic obstructive pulmonary disease (COPD) containing as an active ingredient a lecithinized superoxide dismutase represented by the following general formula (I): SOD?(Q?B)m??(I) (in the formula SOD? represents a residue of the superoxide dismutase; Q represents a chemical crosslinking; B represents a residue without a hydrogen atom of a hydroxyl group of lysolecithin having the hydroxyl group at the 2-position of glycerol; m is the average number of bonds of lysolecithin to one molecule of superoxide dismutase and represents an integer of 1 or more). The ameliorating agent for COPD is intravenously administered or inhalation-administrated.Type: ApplicationFiled: September 20, 2013Publication date: January 23, 2014Applicant: LTT Bio-Pharma Co., Ltd.Inventor: Toru MIZUSHIMA
-
Patent number: 8431614Abstract: There is provided a novel loxoprofen derivative that has no side effect such as a gastrointestinal disorder and also has excellent anti-inflammatory and analgesic effects and is represented by the following formula (I) or (II): (wherein R1 and R2 each represent a halogen atom or a substituted or unsubstituted phenyl group) or a pharmacologically acceptable salt thereof. In the derivative, the halogen atom is selected from a chlorine atom, a bromine atom, a fluorine atom, and an iodine atom, and a substituent of the substituted phenyl group is a halogen atom, a hydroxyl group, a substituted or unsubstituted lower alkyl group, a lower alkylthio group, a lower alkoxy group, a nitro group, an amino group, or a carboxyl group.Type: GrantFiled: February 18, 2010Date of Patent: April 30, 2013Assignees: LTT Bio-Pharma Co., Ltd., National University Corporation Kumamoto UniversityInventors: Toru Mizushima, Masami Ohtsuka, Yoshinari Okamoto, Naoki Yamakawa
-
Publication number: 20120121008Abstract: Required-bandwidth obtaining units are provided in respective function blocks, and each output required-bandwidth information representing the required bandwidth of a corresponding function block based on the horizontal frequency and the number of effective pixels per period of a horizontal synchronization signal. A memory bus arbiter calculates the sum of the required bandwidths of all the function blocks based on the required-bandwidth information, and determines whether or not the sum of the required bandwidths of all the function blocks exceeds the entire bandwidth of the data bus. If it is determined that the sum of the required bandwidths exceeds the entire bandwidth, the required bandwidth of at least one of the function blocks is reduced, while if it is determined that the sum of the required bandwidths does not exceed the entire bandwidth, all the function blocks access the memory using the required bandwidths at the time of required bandwidth calculation.Type: ApplicationFiled: January 24, 2012Publication date: May 17, 2012Applicant: Panasonic CorporationInventor: Toru MIZUSHIMA
-
Publication number: 20120034202Abstract: An ameliorating agent for chronic obstructive pulmonary disease (COPD) containing as an active ingredient a lecithinized superoxide dismutase represented by the following general formula (I): SOD?(Q-B)m??(I) (in the formula SOD? represents a residue of the superoxide dismutase; Q represents a chemical crosslinking; B represents a residue without a hydrogen atom of a hydroxyl group of lysolecithin having the hydroxyl group at the 2-position of glycerol; m is the average number of bonds of lysolecithin to one molecule of superoxide dismutase and represents an integer of 1 or more). The ameliorating agent for COPD is intravenously administered or inhalation-administrated.Type: ApplicationFiled: March 2, 2010Publication date: February 9, 2012Applicant: LTT Bio-Pharma Co., Ltd.Inventor: Toru Mizushima
-
Publication number: 20120016158Abstract: There is provided a novel loxoprofen derivative that has no side effect such as a gastrointestinal disorder and also has excellent anti-inflammatory and analgesic effects and is represented by the following formula (I) or (II): (wherein R1 and R2 each represent a halogen atom or a substituted or unsubstituted phenyl group) or a pharmacologically acceptable salt thereof. In the derivative, the halogen atom is selected from a chlorine atom, a bromine atom, a fluorine atom, and an iodine atom, and a substituent of the substituted phenyl group is a halogen atom, a hydroxyl group, a substituted or unsubstituted lower alkyl group, a lower alkylthio group, a lower alkoxy group, a nitro group, an amino group, or a carboxyl group.Type: ApplicationFiled: February 18, 2010Publication date: January 19, 2012Applicants: LTT BIO-PHARMA CO., LTD., National University Corporation, Kumamoto UniversityInventors: Toru Mizushima, Masami Ohtsuka, Yoshinari Okamoto, Naoki Yamakawa
-
Publication number: 20110262420Abstract: An inhalant containing a lecithinized superoxide dismutase (hereinafter referred to as PC-SOD) which effectively exerts the effect of superoxide dismutase (SOD) as an active ingredient, particularly for treatment of idiopathic (acute) or chronic interstitial pneumonia, is provided. The inhalant includes a PC-SOD represented by the following general formula (I): SOD?(Q?B)m??(I) (wherein SOD? is a residue of the superoxide dismutase; Q is a chemical crosslinking; B is a residue without a hydrogen atom of a hydroxyl group of lysolecithin having the hydroxyl group at the 2-position of glycerol; and m is the average number of bonds of lysolecithin to one molecule of superoxide dismutase and is an integer of 1 or more).Type: ApplicationFiled: November 9, 2009Publication date: October 27, 2011Applicant: LTT Bio-Pharma Co., Ltd.Inventor: Toru Mizushima
-
Publication number: 20110262548Abstract: A PGE1 derivative is provided which has an excellent sustained, slow-release PGE1 action. In addition, a PGE1-derivative-containing nanoparticle produced using this PGE1 derivative is provided, which effectively targets an affected site, has excellent drug slow-release properties, and has reduced side effects. This PGE1-derivative-containing nanoparticle is a nanoparticle containing a prostaglandin E1 derivative represented by the following formula (1) (wherein n denotes an integer of 1 to 12), obtained by hydrophobicizing the prostaglandin E1 derivative with a metal ion, and reacting the hydrophobicized prostaglandin E1 derivative with poly L-lactic acid or a poly(L-lactic acid/glycolic acid) copolymer and a poly DL- or L-lactic acid-polyethylene glycol block copolymer or a poly(DL- or L-lactic acid/glycolic acid)-polyethylene glycol block copolymer.Type: ApplicationFiled: October 16, 2009Publication date: October 27, 2011Applicant: LTT Bio-Pharma Co., Ltd.Inventors: Toru Mizushima, Masami Ohtsuka, Yoshinari Okamoto
-
Publication number: 20100129456Abstract: A nanoparticle containing a low-molecular-weight drug having a negatively charged group is provided that is effectively targeted to an affected site, is capable of sufficiently sustained release of the drug, and has a reduced tendency to accumulate in the liver to cause reduced side effects. The nanoparticle containing a low-molecular-weight drug having a negatively charged group is obtained by hydrophobicizing the low-molecular-weight drug having a negatively charged group with a metal ion, and reacting the hydrophobicized drug with poly L-lactic acid or poly(L-lactic acid/glycolic acid) copolymer and poly DL- or L-lactic acid-polyethylene glycol block copolymer or poly(DL- or L-lactic acid/glycolic acid)-polyethylene glycol block copolymer.Type: ApplicationFiled: April 11, 2008Publication date: May 27, 2010Applicant: LTT Bio-Pharma Co., Ltd.Inventors: Tsutomu Ishihara, Yutaka Mizushima, Ayako Mizushima, Toru Mizushima
-
Publication number: 20080113014Abstract: A method for screening for compounds or salts thereof, in particular nonsteroidal anti-inflammatory compounds or salts thereof, that are safe for gastric mucosa and cause little gastrointestinal side effects. The method uses a particular liposome to serve as a cell membrane model. The liposome encapsulates a fluorescent dye, in particular, calcein and is formed of phospholipids, such as phosphatidylcholine, phosphatidylglycerol, phosphatidylserine, and phosphatidylinositol. A test compound is allowed to react with the liposome and the leakage of the fluorescent dye from the liposome is evaluated. As a result, compounds safe for gastric mucosa, in particular, anti-inflammatory compounds can be screened.Type: ApplicationFiled: December 15, 2004Publication date: May 15, 2008Applicant: LTT BIO-PHARMA CO., LTD.Inventors: Toru Mizushima, Yutaka Mizushima
-
Publication number: 20020015029Abstract: An on-screen display device comprises a video signal generation circuit for generating a video signal including an information signal for displaying information on a display screen, a horizontal sync signal, and a color burst signal; a signal conversion circuit for compressing the amplitude of an input signal so that the input signal can exist at a level higher than the level of the horizontal sync signal, and shifting the level of the input signal so that the input signal can exist at a level hither than the level of the horizontal sync signal, thereby generating a first signal; and an output control circuit for outputting the video signal when the information signal is displayed on the display screen, and outputting the first signal when the information signal is not displayed. Therefore, the amplitude level of an external input signal is prevented from becoming lower than the pedestal level, whereby information such as characters can be reliably superimposed on a noise signal.Type: ApplicationFiled: June 29, 2001Publication date: February 7, 2002Inventors: Toru Mizushima, Yasuhiko Tomikawa